Why data on three patients were worth $1 billion for Sarepta
Yesterday, Sarepta Therapeutics said that three patients with a form of muscular dystrophy showed greater production of a key muscle protein after getting the company’s in-development gene therapy. The news sent Sarepta up about 8%, adding $1 billion to its market value.
That might seem like an incongruous reaction, but, as STAT’s Adam Feuerstein reports, the early data have broad implications for Sarepta’s future.
The gene therapy in question, SRP-9003, treats a subset of patients with the already rare limb-girdle muscular dystrophy. But it shares the same viral backbone as SRP-9001, a gene therapy for the more common Duchenne muscular dystrophy. In the eyes of Wall Street, early signs that the Sarepta’s limb-girdle gene therapy is safe and effective bode well for the future of SRP-9001, which will have key data of its own early next year.
Read more.
That might seem like an incongruous reaction, but, as STAT’s Adam Feuerstein reports, the early data have broad implications for Sarepta’s future.
The gene therapy in question, SRP-9003, treats a subset of patients with the already rare limb-girdle muscular dystrophy. But it shares the same viral backbone as SRP-9001, a gene therapy for the more common Duchenne muscular dystrophy. In the eyes of Wall Street, early signs that the Sarepta’s limb-girdle gene therapy is safe and effective bode well for the future of SRP-9001, which will have key data of its own early next year.
Read more.
.png)
No hay comentarios:
Publicar un comentario